Antibodies

#Antibodies #Drug development #Drug discovery #Guide

DDW Therapeutic Antibody Guide

Download the exclusive Guide and read about: The future of therapeutic antibodies From the top: Shining the spotlight on an industry leader The major disease areas for therapeutic antibodies… Read More

#DDW eBooks #DDW Guides

#Allergy #Alzheimer's #Antibodies #Artificial intelligence (AI) #Autism #Cancer drug targets #Cancer research #Drug development #Influenza #Microbiome #Monoclonal antibodies

New DDW Highlights episode live now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we have heard about a number of studies that demonstrate an inventive… Read More

#News

#Allergy #Alzheimer's #Antibodies #Artificial intelligence (AI) #Autism #Cancer drug targets #Cancer research #Drug development #Influenza #Microbiome #Monoclonal antibodies

This week in drug discovery (26-30 June)  

News round-up for 26-30 June by DDW Digital Content Editor Diana Spencer. This week we have heard about a number of studies that demonstrate an inventive solution to an old problem, either through the use of an original approach or new, advanced technology. Whether… Read More

#News

#Alchemab Therapeutics #Alzheimer's #Antibodies #Therapeutics

Alchemab unveils newly discovered Alzheimer’s candidate 

Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, has unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s candidate.   The data was announced at the Antibody Industrial Symposium in Tours, France, June 22-23, 2023.  ATLX-1088 is a potential… Read More

#News

T cells
#Antibodies #Cancer research #Immunotherapy #Oncology #T cell activation #Transcriptomics

Discovery could lead to more efficient cancer therapies

Scientists from Japan have identified regulator CD69, which controls the differentiation of CD8+ T cells within tumour-draining lymph nodes, thereby regulating anti-tumour immunity. Future cancer treatment based on antibodies against CD69 could enhance anti-tumour immune responses of CD8+ T cells and lead to more efficient cancer… Read More

#Cancer Research #News

Peanuts
#Allergy #Antibodies #Antibody #IgGenix #Monoclonal antibodies

Could a monoclonal antibody treat peanut allergy?

IgGenix has made advances towards a peanut allergy therapeutic based on IgG4 monoclonal antibodies. The company’s research data was presented during the 2023 European Academy of Allergy and Clinical Immunology (EAACI) Congress, in Hamburg, Germany. The data shows that nearly all peanut-specific IgE antibodies… Read More

#News

#Antibodies #Antibody drug conjugate (ADC) #Apexigen #Mergers and acquisitions #Oncology #Pyxis Oncology

Pyxis Oncology to acquire antibody therapeutics company Apexigen

Pyxis Oncology has announced a definitive agreement by which it will acquire Apexigen in an all-stock transaction for an implied value of $0.64 per Apexigen share. For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares of its common stock, par value $0.001 per share, for a total enterprise… Read More

#Business & Investment #News

Adcendo Lab
#Antibodies #Antibody drug conjugate (ADC) #Biotech #Drug development #Seed funding

Financing ensures development of Adcendo’s ADC asset 

Adcendo, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, has completed a successful Series A extension financing round, raising a further €31 million, following the €51 million Series A financing in April 2021. Read More

#News

Gut microbiome
#Antibodies #Clinical trials #Destiny Pharma #Gut microbiome #Microbiology

Landmark trial data on successful gut colonisation

Data generated from a C. difficile infection (CDI) model study on the ability of M3 (NTCD-M3), a non-toxigenic C. difficile strain, shows successful gut colonisation following administration of fidaxomicin and has been peer-reviewed and published in Microbiology Spectrum. The paper by Destiny Pharma, a UK-based clinical stage biotechnology company focused… Read More

#News

#Absci #AI / data analytics / healthtech / informatics #Antibodies #Artificial intelligence (AI) #Drug discovery #Interview

How generative AI could improve drug discovery

Listen to this article on the DDW Podcast: Absci is a generative artificial intelligence (AI) drug creation company with goals of bringing better biologics to patients more quickly. Here, DDW Editor Reece Armstrong speaks to Sean McClain, the Founder and CEO of Absci about how generative AI is being used within… Read More

#Exclusive Content

Antibody drug conjugate
#AI / data analytics / healthtech / informatics #Antibodies #Antibody drug conjugate (ADC) #Big pharma #Drug development #Precision medicine

A personal view on antibody drug development

Oliver Schon, PhD, is VP Research & Development at BiVictriX Therapeutics, a UK-based emerging drug discovery and development company generating a pioneering first-in-class next-generation ADC anti-cancer therapeutics which exhibit superior selectivity towards cancer. Dr Schon is applying his broad expertise from lead discovery to manufacture in order to progress differentiated,… Read More

#Exclusive Content

#Antibodies #Antibody-based therapeutics #Bio-Rad Laboratories #In Focus Report #Monoclonal antibodies

The future of antibody based drugs: Where are the opportunities?

This report will:   Provide an overview of the monoclonal antibody (mAbs) industry: market value, key on the future of antibody-based drug players, opportunities and the future  Explore what’s next for antibody-based drugs and where the opportunity is coming from  Include an interview Bio-Rad’s… Read More

#DDW eBooks #Intelligence

Antibodies
#Antibodies #Antibody-based therapeutics #Bio-Rad Laboratories #In Focus Report #Monoclonal antibodies

DDW In Focus e-report on the future of antibody-based drugs

Created by DDW and sponsored by Bio-Rad, The future of antibody-based drugs: Where are the opportunities and what does the future hold? is a free In Focus report, available here.  This report will:   Provide an overview of the monoclonal… Read More

#News

#Antibodies #Drug discovery #Events #High throughput screening #Protein inhibitor

Symposium: Unlock high-throughput biology

The Carterra 2023 Symposia Series ‘Unlocking High-Throughput Biology and Drug Discovery’ is now open for registrations. Join industry-leading scientists from GSK, Oxford University, LifeArc, Alloy Therapeutics, Sanofi, and Carterra on April 19, 2023 in Cambridge, UK for this one-day, science-filled experience. Learn about the current advancements… Read More

#News

#Antibodies #Cancer research #Cancer vaccine #DDW Highlights podcast #Drug discovery #Immuno-oncology #Immunotherapy #Oncology

New episode of the DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  As March draws to a close, this week’s key announcements have demonstrated the breadth of… Read More

#News